All Articles

For patients with hormone receptor–positive, HER2-negative metastatic breast cancer, response rates for platinum-based chemotherapy were lower than historically observed in patients with triple-negative breast cancer, associated with poor outcomes.

In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing.

While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.

Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.

Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.

In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.

In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.

Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.

The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.